← Back to Screener
SpyGlass Pharma, Inc. Common Stock (SGP)
Price$24.52
Favorite Metrics
Price vs S&P 500 (4W)-13.57%
Market Capitalization$833.66M
All Metrics
Price vs S&P 500 (YTD)-8.36%
10-Day Avg Trading Volume0.08M
EPS (Annual)$-2.50
ROI (Annual)-75.44%
Cash / Share (Quarterly)$3.37
ROA (Last FY)-68.82%
Cash Flow / Share (Annual)$-2.07
P/B Ratio7.89x
Net Income / Employee (Annual)$-1
EPS Incl Extra (Annual)$-2.50
Current Ratio (Annual)12.67x
Quick Ratio (Quarterly)12.57x
3-Month Avg Trading Volume0.14M
52-Week High$32.44
EPS Excl Extra (Annual)$-2.50
Quick Ratio (Annual)12.57x
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)12.67x
Revenue / Employee (Annual)$0
Cash / Share (Annual)$3.37
ROE (Last FY)-75.44%
EPS Basic Excl Extra (Annual)$-2.50
Total Debt / Equity (Quarterly)0.00x
Revenue / Share (Annual)$0.00
Year-to-Date Return-5.53%
5-Day Price Return4.48%
EPS Normalized (Annual)$-2.50
Month-to-Date Return-3.74%
EBITD / Share (Annual)$-2.58
Beta1.65x
52-Week Low$20.15
Analyst Recommendations
Apr 2026
4.44
Industry Peers — Surgical & Medical Instruments(109)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
SGPSpyGlass Pharma, Inc. Common Stock | — | — | — | — | $24.52 |
SYKStryker Corporation | 5.17x | 11.84% | 64.57% | 19.43% | $338.34 |
BSXBoston Scientific Corp. | 4.58x | 15.16% | 69.01% | 18.00% | $60.99 |
MMM3M Company | 3.21x | -4.97% | 39.92% | 18.55% | $151.40 |
MDLNMedline Inc. Class A common stock | 2.20x | — | 26.44% | 7.78% | $48.26 |
BDXBecton, Dickinson and Co. | 2.06x | 6.32% | 46.42% | 12.15% | $158.64 |
RMDResMed Inc. | 6.07x | 11.72% | 60.85% | 33.70% | $226.14 |
DXCMDexCom, Inc. | 5.33x | 19.33% | 62.09% | 19.56% | $64.62 |
WSTWest Pharmaceutical Services, Inc. | 6.29x | 7.44% | 35.91% | 19.03% | $278.00 |
PODDInsulet Corporation | 5.19x | 24.53% | 71.63% | 12.92% | $200.87 |
PENPenumbra, Inc. | 9.24x | 20.16% | 67.14% | 13.48% | $329.71 |
About
SpyGlass Pharma is a late-stage biopharmaceutical company developing long-acting drug delivery systems for chronic eye conditions. The company is advancing two programs: the BIM-IOL System, which delivers glaucoma treatment during cataract surgery, and the BIM-DRS for glaucoma patients not undergoing surgery. Both programs leverage sustained drug delivery of approved medicines to address unmet treatment needs in ophthalmology.